| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Erenumab Basic information |
| Product Name: | Erenumab | | Synonyms: | Erenumab;Research Grade Erenumab(DHH31001);Erenumab (anti-CALCRL);AMG-334;Research Grade Erenumab | | CAS: | 1582205-90-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Erenumab Structure]() |
| | Erenumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Erenumab Usage And Synthesis |
| Uses | Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine[1]. | | References | [1] Goadsby PJ, Reuter U, Hallstrm Y, et al. A Controlled Trial of Erenumab for Episodic Migraine.N Engl J Med. 2017;377(22):2123-2132. DOI:10.1056/NEJMoa1705848 |
| | Erenumab Preparation Products And Raw materials |
|